AUTHORS
Lindsey Elizabeth Roeker, MD, Jennifer A. Woyach, MD2, Toby A. Eyre, MBChB, DipMedEd, MRCP, MD3, Alessandra Ferrajoli III, MD4, Constantine S. Tam, MD,MBBS5, Pier Luigi Zinzani, MD, PhD6, Prioty Islam, MD7, Ryan Jacobs, MD8, Ian W. Flinn, MD, PhD9, Andrea Sitlinger, MD10, Alan Skarbnik, MD11, Seema Ali Bhat, MD12, Nicole Lamanna, MD13, Versha Banerji, MD14, Carolyn Owen, MD15, William G. Wierda, MD, PhD16, Suhyun Kang, PhD17, Min Chen, PhD18, Bastien Nguyen, PhD19, Anne Fink20, Karen Lee Lee Chung, PhD21, Justin L. Ricker, PhD22, Matthew S Davids, MD, MMSc23, Yucai Wang, MD, PhD24
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 The Ohio State University Comprehensive Cancer Center, Columbus, United States
3 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, United Kingdom
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 Alfred Hospital, Melbourne, Victoria, Australia
6 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Atrium Health Levine Cancer, Charlotte, North Carolina, United States
9 Tennessee Oncology, Nashville, Tennessee, United States
10 Duke University Medical Center, Durham, North Carolina, United States
11 Novant Health Cancer Institute, Charlotte, North Carolina, United States
12 The Ohio State University Comprehensive Cancer Center, Columbus, United States
13 Columbia University Medical Center, New York, New York, United States
14 Paul Albrechtsen Research Institute, Cancer Care Manitoba, and University of Manitoba, Winnipeg, Canada
15 Tom Baker Cancer Centre, Calgary, Canada
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 Eli Lilly and Company, Indianapolis, Indiana, United States
18 Eli Lilly and Company, Indianapolis, Indiana, United States
19 Eli Lilly and Company, Indianapolis, Indiana, United States
20 Eli Lilly and Company, Indianapolis, Indiana, United States
21 Eli Lilly and Company, Indianapolis, Indiana, United States
22 Eli Lilly and Company, Indianapolis, Indiana, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Background
Pirtobrutinib, a highly selective, non-covalent Bruton tyrosine kinase inhibitor (ncBTKi), is approved for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) following prior systemic therapy that includes a covalent BTKi (cBTKi). Data from the phase 3 BRUIN CLL-322 trial demonstrated that pirtobrutinib combined with venetoclax-rituximab (PVR) showed significant improvement in progression-free survival (PFS) over venetoclax-rituximab (VR) in patients with previously treated R/R CLL/SLL, with no new safety concerns. This analysis evaluates the efficacy and safety of PVR vs VR in the North American subgroup of patients enrolled in BRUIN CLL-322, the population most relevant to US and Canada practice. The aim was to determine consistency with the global results.
Methods
In BRUIN CLL-322 (NCT04965493), patients were randomized 1:1 to PVR or VR, stratified by del(17p) status and prior cBTKi experience. Patients with prior exposure to ncBTKi or BCL2i were excluded. Both arms received venetoclax (25 cycles [C]) and rituximab (6C); the PVR arm also received fixed-duration pirtobrutinib (28C), with a 3C pirtobrutinib-rituximab lead-in before venetoclax initiation. The primary endpoint was IRC-assessed PFS (iwCLL 2018). Secondary endpoints included investigator (INV)-assessed PFS, time-to-next treatment (TTNT), overall survival (OS), overall response rate (ORR), and safety. Minimal residual disease (MRD) analyses (clonoSEQ®) were exploratory. The current exploratory subgroup analysis focused on patients enrolled in North America. Time-to-event endpoints were assessed for PVR vs VR using the Kaplan-Meier method and stratified log-rank tests. Undetectable MRD4 (uMRD4) rate was compared using Fisher’s test. P-values <0.05 were considered statistically significant and not adjusted for multiplicity.
Results
In BRUIN CLL-322, 639 patients were randomized. Of those, 214 patients were enrolled in North America (USA and Canada) (PVR, n=104; VR, n=110). Median age was 69.0 yrs (range, 34.0-87.0); 70.1% were male; 90.7% white, 5.6% black, 1.9% Hispanic, and 1.9% other. Median number of prior treatments was 2 (range, 1-7). 90.7% had received prior cBTKi, including 61.7% who discontinued prior cBTKi due to progressive disease. 67.3% had received prior anti-CD20 antibodies and 51.9% had prior chemotherapy. 43.0% had del17p and/or TP53 mutation, balanced between treatment arms. PVR demonstrated superiority in IRC-PFS vs VR in the North America subgroup (stratified HR, 0.406; 95% CI, 0.221-0.746; P=0.0028); median PFS was not estimable (NE) (95% CI, NE, NE) with PVR vs 39.72 months (95% CI, 36.14, NE) with VR. Twenty-four-month PFS rate was 90.3% with PVR vs 71.8% with VR. INV-PFS results were consistent, favoring PVR (stratified HR, 0.317; 95% CI, 0.168-0.600; P=0.0002). TTNT favored PVR vs VR (stratified HR, 0.308; 95% CI, 0.158-0.601; P=0.0003). OS data are immature (stratified HR, 0.757; 95% CI, 0.299-1.913; P=0.5521). ORR was 91.3% with PVR vs 78.2% with VR, including complete response (CR)/CR with incomplete bone marrow recovery rates of 40.4% vs 30.0%, respectively. Peripheral blood uMRD4 rate at the end of treatment in those with evaluable samples was higher with PVR (43/48 [89.6%] vs 29/45 [64.4%]; P=0.006). Rates of any grade adverse events (AEs) for PVR vs VR were 100.0% and 97.2%, and grade ≥3 AEs were 75.5% vs 67.0%, respectively. Grade ≥3 AEs of interest included neutropenia (38.2% vs 34.9% [febrile neutropenia 1.0% vs 4.7%]) and tumor lysis syndrome (1.1% vs 3.8%). Rates of any grade infections were 75.5% vs 64.2% in PVR vs VR, including grade ≥3 infections in 25.5% vs 11.3% (including one grade 5 event in VR). Rates of any grade atrial fibrillation/flutter were 5.9% vs 2.8%, including grade 3 rates in 2.9% vs 0.9%. Treatment regimen discontinuation rates due to treatment-related AEs were 5.9% vs 2.8%.
Conclusions
The BRUIN CLL-322 trial demonstrated superiority of fixed-duration PVR vs VR in the North American subgroup of patients with previously treated R/R CLL, including statistically significant and clinically meaningful improvements in PFS and TTNT over VR with a manageable safety profile reflecting the added agent. The findings are consistent with the global BRUIN CLL-322 results and support fixed-duration PVR as a potential new standard of care for previously treated CLL/SLL in North America.
DISCLOSURES
Lindsey Elizabeth Roeker, MD: Abbott Laboratories - Current equity holder in publicly-traded company; Pfizer - Research Funding; Loxo Oncology - Research Funding; Dren Bio - Research Funding; Aptose Biosciences - Research Funding; Genentech - Research Funding; AbbVie - Research Funding; AstraZeneca - Research Funding; Adaptive Biotech - Research Funding; Qilu Puget Sound Biotherapeutics - Research Funding; AbbVie - Consultancy (Includes expert testimony); DAVA - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); TG Therapeutics - Consultancy (Includes expert testimony); Medscape - Consultancy (Includes expert testimony); Pharmacyclics - Consultancy (Includes expert testimony); Curio - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); PeerView - Consultancy (Includes expert testimony); Loxo Oncology - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony)